CymaBay Therapeutics (CBAY) Tops Q4 EPS by 8c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
CymaBay Therapeutic (CBAY) PT Raised to $19 at SunTrust Robinson Humphrey; 'Remain Bullish... Would be Strong Buyers'
March 16, 2018 3:02 PM EDTSunTrust Robinson Humphrey raised its price target on CymaBay Therapeutic (NASDAQ: CBAY) to $19.00 (from $15.00) while maintaining a Buy rating.
Analyst Edward Nash comments, "we see 2018 as a critical year for CymaBay as the company is expected to report 26-week and... More
